Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 21, 2014; 20(3): 786-794
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.786
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.786
Adverse events | Statistics |
Fatigue | 29 (65.9) |
Grade 1 | 11 (25.0) |
Grade 2 | 11 (25.0) |
Grade 3 | 7 (15.9) |
Bleeding | 7 (15.9) |
Grade 1 | 3 (6.8) |
Grade 2 | 1 (2.3) |
Grade 3 | 3 (6.8) |
Hand-foot syndrome | 14 (31.8) |
Grade 1 | 7 (15.9) |
Grade 2 | 7 (15.9) |
Grade 3 | 0 (0.0) |
Diarrhea | 15 (34.1) |
Grade 1 | 6 (13.6) |
Grade 2 | 8 (18.2) |
Grade 3 | 1 (2.3) |
Hepatic grade 31AEs | 8 (18.2) |
Other AEs2 | 20 (45.5) |
- Citation: Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Costanzo FD, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794
- URL: https://www.wjgnet.com/1007-9327/full/v20/i3/786.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i3.786